On February 26, 2026, PSM was glad to see the Indiana legislature pass SB 282, a bill that strengthens compounding and medical spa regulation to keep Indiana patients safer
The broader 2026 context matters: as of May 2026, the FDA has proposed regulatory changes affecting compounded semaglutide and tirzepatide, with a public comment period closing June 29, 2026
Research designed around anxiolytic outcomes (anxiety paradigms, stress-response models) is the Selank space
GMP Quality Assured
Anti-Aging Potential: Some studies suggest that IGF-1 LR3 may have anti-aging properties, promoting skin health and vitality
It supports the immune system, promotes the production of collagen, and helps in repairing damaged skin cells